Trials / Completed
CompletedNCT06139393
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
Study on Efficacy and Safety of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 765 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR091506 tablets + placebo of febuxostat tablets | HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28. |
| DRUG | febuxostat tablets + placebo of HR091506 tablets | febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28. |
Timeline
- Start date
- 2023-12-14
- Primary completion
- 2025-08-18
- Completion
- 2025-09-04
- First posted
- 2023-11-18
- Last updated
- 2025-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06139393. Inclusion in this directory is not an endorsement.